-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
European Market for Continuous Glucose Monitoring
Frost & Sullivan, May 2010, Pages: 110
This Frost & Sullivan research service titled European Market for Continuous Glucose Monitoring provides a comprehensive analysis of the European market for continuous glucose monitoring (CGM). This research service includes an analysis of the factors driving the market growth, challenges faced by the industry and opportunities within the market in the long term. In this research, Frost & Sullivan's expert analysts thoroughly examine the following regions: Benelux, Germany, France, Italy, Scandinavia, Spain and the United Kingdom.
Market Overview
Technologically Advanced and User-friendly Patient Monitoring Devices to Spur Growth of the European Continuous Glucose Monitoring Market
An increase in the aging population in the western European region along with the higher incidence of fatal diseases such as cardiovascular diseases, diabetes and stroke, spurring the need for regular monitoring of the glucose levels of patients. Therefore, pioneering technology in the product line at considerably lower rates is sought after by the medical community to help in proper therapy management for diabetes, prevent the occurrence of cardiovascular disorder, reduce patient stay in hospital and lower the costs incurred by patients. Currently, the multi-parameter mid-range patient monitor devices market is in its development stage. The most important driver for the CGM market in Europe is the need for a convenient, patient-friendly and affordable device that facilitates superior therapy management for diabetes. Unlike the more tedious traditional method of monitoring glucose, CGM devices are hassle-free and offer superior benefits.
However, CGM is not reimbursed and the per sensor cost is steep. This restrains patients from purchasing the devices. “The traditional finger-stick method offers glucose monitoring at much lower rates and is reimbursed all across Europe,” explains the analyst. “On the other hand, while using a CGM device the patient has to buy a starter kit and pay for the disposable sensors year-on-year, making the method of treatment more expensive.”
Collaboration with established local companies will help manufacturers provide effective services and, at the same time, maintain profit margins. Furthermore, integration of continuous glucose monitors with insulin pumps will pave way for reimbursement options for manufactures, thus reducing the total cost incurred by patients. “To enable the market participants to include such systems in the reimbursable category, significant clinical evidence suggesting that the device is essential for the patient’s well-being is required,” concludes the analyst. “Moreover, when CGM is integrated with insulin pumps, the product will become reimbursable as it is more likely to fall under the medically essential classification of insurance agencies.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
By Region:
- Benelux
- Germany
- France
- Italy
- Scandinavia
- Spain
- The United Kingdom
1 | AN ANALYSIS OF CONTINUOUS GLUCOSE MONITORING MARKET
- Continuous Glucose Monitoring Market - Europe
- - 1. Continuous Glucose Monitoring Market - An Overview
List of Figures
Continuous Glucose Monitoring Market: Revenue Forecasts (Europe), 2008-2016
Continuous Glucose Monitoring Market: Revenue Forecasts (Benelux), 2008-2016
Continuous Glucose Monitoring Market: Revenue Forecasts (France), 2008-2016
Continuous Glucose Monitoring Market: Revenue Forecasts (Germany), 2008-2016
Continuous Glucose Monitoring Market: Revenue Forecasts (Italy), 2008 -2016
Continuous Glucose Monitoring Market: Revenue Forecasts (Scandinavia), 2008-2016
Continuous Glucose Monitoring Market: Revenue Forecasts (Spain), 2008-2016
Continuous Glucose Monitoring Market: Revenue Forecasts (The United Kingdom), 2008-2016
Decision Support Database: Total Healthcare Expenditure (Western Europe), 2002-2012
Decision Support Database: Government Healthcare Expenditure (Western Europe), 2002-2012
Decision Support Database: Total Number of Hospital Beds (Western Europe), 2002-2012
Decision Support Database: Prevalence of Diabetes (Western Europe), 2002-2012
Decision Support Database: New cases of Diabetes (Western Europe), 2002-2012
Decision Support Database: Prevalence percent of Diabetes (Western Europe), 2002-2012
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
